基于疗效的阿柏西普治疗视网膜中央静脉阻塞方案 - Suppr | 超能文献

Efficacy-Based Aflibercept Treatment Regimen for Central Retinal Vein Occlusion.

作者信息

Shimura Masahiko, Utsumi Takuya, Imazeki Makoto, Yasuda Kanako, Noma Hidetaka

机构信息

Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

出版信息

Ophthalmol Retina. 2021 Nov;5(11):1177-1179. doi: 10.1016/j.oret.2021.06.008. Epub 2021 Jun 24.

DOI:10.1016/j.oret.2021.06.008

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Efficacy-Based Aflibercept Treatment Regimen for Central Retinal Vein Occlusion.基于疗效的阿柏西普治疗视网膜中央静脉阻塞方案

Ophthalmol Retina. 2021 Nov;5(11):1177-1179. doi: 10.1016/j.oret.2021.06.008. Epub 2021 Jun 24.

2

EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.阿柏西普与雷珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的疗效及频率。

Retina. 2018 Sep;38(9):1795-1800. doi: 10.1097/IAE.0000000000001782.

3

Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.阿柏西普和雷珠单抗“治疗并监测”方案用于非缺血性视网膜分支静脉阻塞继发黄斑水肿的疗效

Int Ophthalmol. 2019 Jan;39(1):145-153. doi: 10.1007/s10792-017-0798-6. Epub 2017 Dec 22.

4

Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.阿柏西普治疗既往治疗过的与视网膜中央静脉阻塞相关的黄斑水肿：NEWTON研究的1年结果

Ophthalmol Retina. 2018 Feb;2(2):128-133. doi: 10.1016/j.oret.2017.05.017. Epub 2017 Oct 12.

5

Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.雷珠单抗与阿柏西普治疗视网膜中央静脉阻塞相关黄斑水肿的比较。

Jpn J Ophthalmol. 2017 Jan;61(1):67-73. doi: 10.1007/s10384-016-0476-7. Epub 2016 Sep 22.

6

Aflibercept Treatment for Macular Edema following Branch Retinal Vein Occlusion: Age-Based Responses.阿柏西普治疗分支型视网膜静脉阻塞继发黄斑水肿：基于年龄的反应。

Ophthalmologica. 2020;243(2):94-101. doi: 10.1159/000502042. Epub 2019 Aug 28.

7

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.雷珠单抗与阿柏西普治疗视网膜中央静脉阻塞所致黄斑水肿的18个月真实数据结果

Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1093-1100. doi: 10.1007/s00417-017-3613-1. Epub 2017 Feb 18.

8

Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion.玻璃体内同时注射地塞米松和阿柏西普治疗视网膜静脉阻塞继发难治性黄斑水肿。

Graefes Arch Clin Exp Ophthalmol. 2020 Apr;258(4):787-793. doi: 10.1007/s00417-019-04577-8. Epub 2020 Jan 2.

9

The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.在缺血性中央静脉阻塞继发黄斑水肿的难治性病例中，将雷珠单抗换用阿柏西普的效果。

Klin Monbl Augenheilkd. 2015 Apr;232(4):552-5. doi: 10.1055/s-0035-1545783. Epub 2015 Apr 22.

10

Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.视网膜中央静脉阻塞或半侧视网膜静脉阻塞继发黄斑水肿患者6个月视力和视网膜厚度结果的基线因素：SCORE2研究报告4

JAMA Ophthalmol. 2017 Jun 1;135(6):639-649. doi: 10.1001/jamaophthalmol.2017.1141.

引用本文的文献

1

Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study.改良式阿柏西普治疗并延长方案治疗视网膜中央静脉阻塞性黄斑水肿的疗效：2年前瞻性研究

J Clin Med. 2023 Aug 2;12(15):5089. doi: 10.3390/jcm12155089.

2

New individualized aflibercept treatment protocol for branch retinal vein occlusion with macular edema.伴有黄斑水肿的分支视网膜静脉阻塞的新型个体化阿柏西普治疗方案。

Sci Rep. 2023 Jan 27;13(1):1536. doi: 10.1038/s41598-023-28533-z.